Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Cardiff Oncology Inc (CRDF)

Cardiff Oncology Inc (CRDF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 217,831
  • Shares Outstanding, K 51,134
  • Annual Sales, $ 490 K
  • Annual Income, $ -41,440 K
  • EBIT $ -46 M
  • EBITDA $ -47 M
  • 60-Month Beta 1.89
  • Price/Sales 470.47
  • Price/Cash Flow N/A
  • Price/Book 4.23

Options Overview Details

View History
  • Implied Volatility 89.48% ( -46.85%)
  • Historical Volatility 202.14%
  • IV Percentile 6%
  • IV Rank 10.11%
  • IV High 628.39% on 09/18/24
  • IV Low 28.90% on 05/22/24
  • Put/Call Vol Ratio 0.61
  • Today's Volume 925
  • Volume Avg (30-Day) 3,203
  • Put/Call OI Ratio 0.80
  • Today's Open Interest 36,450
  • Open Int (30-Day) 35,918

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.25
  • Number of Estimates 4
  • High Estimate -0.20
  • Low Estimate -0.29
  • Prior Year -0.21
  • Growth Rate Est. (year over year) -19.05%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.26 +88.50%
on 12/06/24
5.64 -24.46%
on 12/17/24
+1.73 (+68.38%)
since 11/20/24
3-Month
2.26 +88.50%
on 12/06/24
5.64 -24.46%
on 12/17/24
+1.58 (+58.96%)
since 09/20/24
52-Week
1.41 +202.13%
on 12/29/23
6.42 -33.64%
on 03/25/24
+2.82 (+195.83%)
since 12/20/23

Most Recent Stories

More News
Oncology Advancements Accelerate Amid Rising Early-Onset Cancer Diagnoses

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:CRDF),(NASDAQ:PSNL),(NASDAQ:TEM),(NASDAQ:CKPT) EQNX::TICKER_END

ONCY : 0.8310 (-6.36%)
CKPT : 3.75 (+11.28%)
PSNL : 5.75 (+9.32%)
ONC.TO : 1.19 (-9.16%)
TEM : 35.54 (+7.60%)
CRDF : 4.26 (-5.12%)
Oncology Advancements Accelerate Amid Rising Early-Onset Cancer Diagnoses

/CNW/ -- USA News Group News Commentary – The American Cancer Society has published its Advances in Oncology – 2024 Research Highlights, underscoring major...

ONCY : 0.8310 (-6.36%)
CKPT : 3.75 (+11.28%)
PSNL : 5.75 (+9.32%)
ONC.TO : 1.19 (-9.16%)
TEM : 35.54 (+7.60%)
CRDF : 4.26 (-5.12%)
Cancer Care Disruptions Highlight Growing Demand for Innovative Oncology Treatments

/CNW/ -- USA News Group News Commentary – The American Cancer Society recently released its Advances in Oncology – 2024 Research Highlights report that...

ONCY : 0.8310 (-6.36%)
CKPT : 3.75 (+11.28%)
LLY : 767.76 (+1.35%)
ONC.TO : 1.19 (-9.16%)
OSTX : 3.97 (+1.53%)
CRDF : 4.26 (-5.12%)
Cardiff Oncology Reports Promising Initial Results from Phase 2 CRDF-004 Trial of Onvansertib in RAS-Mutated mCRC

Cardiff Oncology's Phase 2 trial shows onvansertib combined with SoC yields 64% ORR in RAS-mut mCRC patients.Quiver AI SummaryCardiff Oncology, Inc. announced positive preliminary results from its Phase...

CRDF : 4.26 (-5.12%)
Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct Offering

CRDF : 4.26 (-5.12%)
Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial

CRDF : 4.26 (-5.12%)
Cardiff Oncology Announces New Patent with Claims for the Use of Onvansertib in Treating KRAS mutated mCRC

CRDF : 4.26 (-5.12%)
Cardiff Oncology: Q3 Earnings Snapshot

Cardiff Oncology: Q3 Earnings Snapshot

CRDF : 4.26 (-5.12%)
Cardiff Oncology Reports Third Quarter 2024 Results and Provides Business Update

CRDF : 4.26 (-5.12%)
Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC

CRDF : 4.26 (-5.12%)

Business Summary

Cardiff Oncology Inc. is a clinical-stage biotechnology company. It engages in developing treatment for cancer patients. The company's product pipeline consists of a Phase 1b/2 study of onvansertib in combination with FOLFIRI/Avastin(R) in KRAS-mutated metastatic colorectal cancer; a Phase 2 study of...

See More

Key Turning Points

3rd Resistance Point 5.02
2nd Resistance Point 4.85
1st Resistance Point 4.55
Last Price 4.26
1st Support Level 4.08
2nd Support Level 3.91
3rd Support Level 3.61

See More

52-Week High 6.42
Fibonacci 61.8% 4.51
Last Price 4.26
Fibonacci 50% 3.91
Fibonacci 38.2% 3.32
52-Week Low 1.41

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar